4 articles
Array Biopharma Inc. challenged the Deputy Controller of Patents' refusal of its pharmaceutical combination patent for a cancer therapy before the Delhi High Court. Did the Controller's reasoning…
The Delhi High Court's Division Bench held that product-to-claim mapping is indispensable for patent infringement, even in anticipatory suits. In a dispute between Zydus Lifesciences and E.R. Squibb…
Daewoong Pharmaceutical challenged the Controller's rejection of its crystalline SGLT inhibitor patent before the Delhi High Court. The core question: does improved dissolution and stability satisfy the Section…
In Frimline v. K-SMATCO, Delhi HC granted interim relief over patent IN 382949, citing strong prima facie infringement of Frimline’s pharmaceutical formulation.